Hylan versus hyaluronic acid for osteoarthritis of the knee: A systematic review and meta-analysis

Arthritis Care and Research

Volumn 57, Issue 8, 2007, Pages 1410-1418

  Reichenbach, Stephan ^a,b   Blank, Sacha ^a   Rutjes, Anne W S ^c,d   Shang, Aijing ^a   King, Elizabeth A ^b   Dieppe, Paul A ^b   Jüni, Peter ^a,b   Trelle, Sven ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Knee; Meta analysis; Osteoarthritis; Viscosupplementation

Indexed keywords

ARTZAL; BIO HYALURONAN; HYALURONIC ACID; HYALURONIC ACID DERIVATIVE; HYLAN; OSTENIL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDEMA; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; KNEE PAIN; META ANALYSIS; OSTEOARTHRITIS; PAIN ASSESSMENT; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SWELLING; SYSTEMATIC REVIEW; WARMING;

ADJUVANTS, IMMUNOLOGIC; AGED; BIOCOMPATIBLE MATERIALS; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MIDDLE AGED; OSTEOARTHRITIS, KNEE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 37349067113     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23103     Document Type: Review

References (51)

1. Fiorentini R. Proceedings of the United States Food and Drug Administration Advisory Panel on Orthopaedic and Rehabilitation Devices. Fairfax (VA): CASET Associates; 1996.
2. Berkowitz D. Proceedings of the United States Food and Drug Administration Advisory Panel on Orthopaedic and Rehabilitation Devices. Fairfax (VA): CASET Associates; 1996.
3. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 1995;3:213-25.
4. Scale D, Wobig M, Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 1994;56:220-32.
5. Martens PB. Bilateral symmetric inflammatory reaction to hylan G-F 20 injection. Arthritis Rheum 2001;44:978-9.
6. Tomas Gil J, Lopez Mateu P, Alegre J. Acute adverse reaction to hylan G-F 20: comment on the article by Martens [letter]. Arthritis Rheum 2003;48:866.
7. Pagnano M, Westrich G. Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthritis Cartilage 2005;13:751-61.
8. Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop Relat Res 2004;419:130-7.
9. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003;290:3115-21.
10. Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. Int J Technol Assess Health Care 2003;19:41-56.
11. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee: a meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2004;86-A:538-45.
12. Arrich J, Piribauer F, Mad P, Schmid D, Klaushofer K, Mullner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005;172:1039-43.
13. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005321.
14. Medina JM, Thomas A, Denegar CR. Knee osteoarthritis: should your patient opt for hyaluronic acid injection? J Fam Pract 2006;55:669-75.
15. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
16. Altman R, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society: results from a workshop. Osteoarthritis Cartilage 1996;4:217-43.
17. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis: consensus development at OMERACT III. J Rheumatol 1997;24:799-802.
18. Juni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol 2006;20:721-40.
19. Juni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi B, et al, for the Swiss Viscosupplementation Trial Group. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum 2007;56:3610-9.
20. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum; 1988.
21. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580-90.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
24. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:1046-55.
25. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999;18:2693-708.
26. Baujat B, Mahe C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med 2002;21:2641-52.
27. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
28. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al, and the International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:26.
29. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 1999;21:1549-62.
30. Zhou G, Wang YR, Zhou ZD, Hu GT. Comparison of two different molecular-weight of sodium hyaluronate on treatment of the osteoarthrosis. Acta Univ Med Second Shanghai 2000;20:361-3.
31. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis: a controlled, randomized, double-blind, parallel-design multicenter study. Rheumatology (Oxford) 2002;41:1240-8.
32. Bayramoglu M, Karatas M, Cetin N, Akman N, Sozay S, Dilek A. Comparison of two different viscosupplements in knee osteoarthritis: a pilot study. Clin Rheumatol 2003;22:118-22.
33. Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K. Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis. Ann Clin Lab Sci 2004;34:330-5.
34. Karatosun V, Unver B, Gocen Z, Sen A. Comparison of two hyaluronan drugs in patients with advanced osteoarthritis of the knee: a prospective, randomized, double-blind study with long term follow-up. Clin Exp Rheumatol 2005;23:213-8.
35. Rolf CG, Engstrom B, Ohrvik J, Valentin A, Lilja B, Levine DW. A comparative study of the efficacy and safety of hyaluronan viscosupplements and placebo in patients with symptomatic and arthroscopy-verified cartilage pathology. J Clin Res 2005;8:183-200.
36. Atamaz F, Kirazli Y, Akkoc Y. A comparison of two different intra-articular hyaluronan drugs and physical therapy in the management of knee osteoarthritis. Rheumatol Int 2006;26:873-8.
37. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2006;14:154-62.
38. Kotevoglu N, Iyibozkurt PC, Hiz O, Toktas H, Kuran B. A prospective randomized controlled clinical trial comparing the efficacy of different molecular weight hyaluronan solutions in the treatment of knee osteoarthritis. Rheumatol Int 2006;26:325-30.
39. Garcia B. A comparative study: adverse reactions to Synvisc but not Hyalgan. In: Annual meeting of the American Academy of Orthopaedic Surgeons; 2004 March 10-14; San Francisco, CA. 2004. Abstract No: P337.
40. Raman R, Dutta, Day N, Shaw CJ, Johnson G. The efficacy of Hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee: a prospective randomized double blind trial [abstract]. Arthritis Rheum 2006;54 Suppl 9:S675.
41. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1998;20:410-23.
42. Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technol Assess 2003;7:1-76.
43. Egger M, Smith GD. Principles of and procedures for systematic reviews. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. London: BMJ; 2001. p. 23-42.
44. Buscemi N, Hartling L, Vandermeer B, Tjosvold L, Klassen TP. Single data extraction generated more errors than double data extraction in systematic reviews. J Clin Epidemiol 2006;59:697-703.
45. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
46. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-9.
47. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA 2002;287:2973-82.
48. Brown DJ, Beinat L. Safety and efficacy of an hyaluronan of 500-730 KDa and Hylan G-F 20 in clinical practice. Osteoarthritis Cartilage 2003;11 Suppl 1:S118.
49. Brown DJ, Wood EV, Hannah HM, Rao VS, Teanby D. Prospective comparison of sodium hyaluronate and hylan G-F 20 in a clinical practice: comment on the concise communication by Martens [letter]. Arthritis Rheum 2004;50:1697-8.
50. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-60.
51. Mulrow CD, Cook DJ, Davidoff F. Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997;126:389-91.